Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

OYE Therapeutics doses first subject in bridging study of intravenous caffeine formulation

Summary by News Medical
OYE Therapeutics Inc., a clinical-stage biotechnology company developing therapies for perioperative and emergency medicine, announced that the first subject has been dosed in its scientific bridging study evaluating OYE-101.

1 Articles

News MedicalNews Medical
Center

OYE Therapeutics doses first subject in bridging study of intravenous caffeine formulation

OYE Therapeutics Inc., a clinical-stage biotechnology company developing therapies for perioperative and emergency medicine, announced that the first subject has been dosed in its scientific bridging study evaluating OYE-101.

·United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

News Medical broke the news in United States on Tuesday, April 7, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

San Diego icon

San Diego

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal